This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma
Blood Cancer Journal Open Access 30 July 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122–1128.
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520.
Engelhardt M, Terpos E, Kleber M, Gay F, Wasch R, Morgan G et al. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 2014; 99: 232–242.
Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116: 679–686.
Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012; 119: 4375–4382.
Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009; 23: 1337–1341.
Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010; 376: 2075–2085.
Gaultney JG, Franken MG, Tan SS, Redekop WK, Huijgens PC, Sonneveld P et al. Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents. J Clin Pharm Ther 2013; 38: 41–47.
Petrucci MT, Calabrese E, Levi A, Federico V, Ceccolini M, Rizzi R et al. Cost of illness in patients with multiple myeloma in Italy: the CoMiM study. Tumori 2013; 99: e193–e202.
Teitelbaum A, Ba-Mancini A, Huang H, Henk HJ . Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data. Oncologist 2013; 18: 37–45.
Burnette BL, Leung N, Rajkumar SV . Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med 2011; 364: 2365–2366.
Ludwig H, Adam Z, Hajek R, Greil R, Tothova E, Keil F et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 2010; 28: 4635–4641.
Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010; 28: 4976–4984.
Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011; 12: 431–440.
Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010; 116: 4745–4753.
Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 2012; 119: 2100–2105.
Acknowledgements
The authors would like to thank Mark Yap and Shanmugapriya Saravanan of McKesson Specialty Health for their support with data collection for this analysis. The authors would also like to thank Iwen Pan of McKesson Specialty Health, Rahul Dhanda, formerly of McKesson Specialty Health, and Abbie Ba-Mancini of Millennium Pharmaceuticals, Inc, Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, for their input into the study design and preliminary analysis. The authors would like to acknowledge Steve Hill of FireKite, an Ashfield company, part of UDG Healthcare plc, for writing support during the development of this manuscript, which was funded by Millennium Pharmaceuticals Inc and complied with Good Publication Practice 2 ethical guidelines (Graf et al., BMJ 2009). This research was sponsored by Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Author contributions
SKK and EM designed the research. SKK, AEE, FKB, MQL, AD, MSD, M-HL, PL, WYC, KD, DR, DP and SVR performed the research. EM, AEE, MSD, M-HL, PL, WYC, KD, DR and DP collected data. MSD, M-HL, PL, WYC and KD performed statistical analysis. SKK, EM, MSD, M-HL, PL, WYC, KD, DR, DP, LN and MQ analyzed and interpreted data. SKK and EM wrote the manuscript. All authors reviewed and revised the draft manuscript, and reviewed and approved the final version for submission.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Dr Kumar has acted as a consultant for Merck, Celgene, Millennium Pharmaceuticals, Inc and Onyx; and has received research funding from Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Celgene, Novartis, Genzyme, Onyx and Cephalon. Ms Ma, Dr Niculescu and Dr Quick are employees of Millennium Pharmaceuticals, Inc. Dr Lacy has received research funding from Celgene Corporation. Dr Dispenzieri has received research funding from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Pfizer, Celgene Corporation and Janssen. Dr Duh, Ms Lafeuille, Mr Lefebvre, Ms Cheng and Ms Dea have received research funding from Millennium Pharmaceuticals, Inc, via engagement with employer Analysis Group Inc. Dr Rembert and Dr Patt are employees of McKesson Specialty Health Ms Engebretson, Dr Buadi and Dr Rajkumar declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Kumar, S., Ma, E., Engebretson, A. et al. Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma. Leukemia 30, 995–998 (2016). https://doi.org/10.1038/leu.2015.225
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.225
This article is cited by
-
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma
Blood Cancer Journal (2018)
-
The proteasome and proteasome inhibitors in multiple myeloma
Cancer and Metastasis Reviews (2017)
-
Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients
Journal of Cancer Research and Clinical Oncology (2016)